These data strongly underline the role of ErbB3 in the rebound of melanoma cell growth following vemurafenib/trametinib treatments and pave the way for the use of anti-ErbB3 mAbs as adjuncts to current therapies in order to obtain a durable control of tumor growth. The gene discussed is ERBB3; the disease is melanoma.